Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo

Morihito Takita, Tomoko Matsumura, Kana Yamamoto, Erika Yamashita, Kazutaka Hosoda, Tamae Hamaki, Eiji Kusumi
doi: https://doi.org/10.1101/2020.04.29.20085449
Morihito Takita
1Department of Internal Medicine, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: takita-ygc@umin.ac.jp
Tomoko Matsumura
1Department of Internal Medicine, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kana Yamamoto
1Department of Internal Medicine, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
2Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku, Tokyo, Japan
3Department of Reproductive, Developmental and Aging Sciences, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Yamashita
2Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazutaka Hosoda
4Department of Pediatrics, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamae Hamaki
2Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiji Kusumi
1Department of Internal Medicine, Navitas Clinic Tachikawa, Tachikawa, Tokyo, Japan
2Department of Internal Medicine, Navitas Clinic Shinjuku, Shinjuku, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Serological evaluation with SARS-CoV-2 specific IgG antibody will be an alternative way to know the pandemic of novel coronavirus disease (COVID-19) if the capacity for diagnostic PCR test is limited. The point-of-care test to detect SARS-CoV-2 specific IgG antibody in peripheral blood (n =202) was performed in two community clinics in Tokyo, Japan. The overall positive rate of SRAS-CoV-2 IgG antibody was 5.9% (95% confidence interval[CI]: 3.1-10.1). Higher rate was observed for healthcare workers (n =55, 9.1 [3.0-20.0]). The limitation on antibody tests includes low sensitivity and potent cross-reactivity with the previous coronavirus. Robust healthcare policy to efficiently monitor COVID-19 spread is warranted in Tokyo.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study was performed by intramural funding of Navitas Clinic.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest We declare no competing interests. The study was performed by intramural funding of Navitas Clinic.

Data Availability

The datasets analyzed during the current study are not publicly available due to ongoing further analyses but are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 05, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo
Morihito Takita, Tomoko Matsumura, Kana Yamamoto, Erika Yamashita, Kazutaka Hosoda, Tamae Hamaki, Eiji Kusumi
medRxiv 2020.04.29.20085449; doi: https://doi.org/10.1101/2020.04.29.20085449
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Preliminary Results of Seroprevalence of SARS-CoV-2 at Community Clinics in Tokyo
Morihito Takita, Tomoko Matsumura, Kana Yamamoto, Erika Yamashita, Kazutaka Hosoda, Tamae Hamaki, Eiji Kusumi
medRxiv 2020.04.29.20085449; doi: https://doi.org/10.1101/2020.04.29.20085449

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9778)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2314)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (505)
  • Infectious Diseases (except HIV/AIDS) (11653)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (697)
  • Pharmacology and Therapeutics (301)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2186)
  • Public and Global Health (4668)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)